In a high-throughput screen aimed at identifying compounds capable of counteracting these CAF-induced effects, abemaciclib and palbociclib emerged as potential agents able to restore ERα signalling in MCF7 breast cancer cells [22]. Here, ESR1 is linked to breast carcinoma.